Navigation Links
Nephros Extends Rights Offering
Date:2/28/2011

ed amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros ESRD products are sold and distributed throughout Europe.

The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. Nephros's DSUs are being evaluated at several major U.S. medical centers for infection control. The DSU has also been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to complete the rights offering; (ii) to continue as a going concern; (iii) to obtain additional funding when needed or on favorable terms; (iv) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (v) to have its technologies a
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nephros Has Commenced Rights Offering
2. Nephros Rights Offering Registration Statement Declared Effective
3. Nephros Reports 2010 Third Quarter Financial Results
4. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
5. Nephros Reports 2010 Second Quarter Financial Results
6. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
7. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
8. Nephros Reports 2010 First Quarter Financial Results
9. Nephros Signs Development Agreement with STERIS
10. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
11. Nephros Reports 2009 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/29/2015)... , May 29, 2015 Educating ... of the Association for the Advancement of Wound ... With support from AAWC,s corporate partners, the ... Portal on the AAWC website at ... wound care pathway with links to various CME/CEU ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA ... financial results for the second quarter and three and six ... expressed in Canadian dollars and in accordance with International Financial ... ESSA recorded a net loss of $5.9 million ($0.35 ... 2015 (Q2-2015), compared to a net loss of $0.4 million ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... Presented at the 132nd Annual Meeting of the American Neurological ... Association in ... presented results from two,Phase III pivotal trials and one open-label ... restless legs,syndrome (RLS). These rotigotine data showed significant drops in ...
... Boehringer Ingelheim,Pharmaceuticals, Inc. today announced that ... full (traditional) approval of Aptivus(R),(tipranavir) capsules. The ... 2005; accelerated approval is a regulatory process ... or life-threatening illnesses. The full,approval of APTIVUS ...
Cached Medicine Technology:Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 2Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 3Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 4Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 2Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 3Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 4Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 6Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 7Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 8
(Date:5/29/2015)... 29, 2015 World Patent Marketing, a ... that it has signed a 10 year licensing agreement ... aims to let people learn about any topic and ... , "This is an exciting day for World Patent ... J. Cooper, CEO and Creative Director of World Patent ...
(Date:5/29/2015)... 29, 2015 Mediaplanet has joined forces ... protection”. Skin Health is a cross-platform campaign with ... markets of New York, Los Angeles, and Chicago, the ... Its digital counterpart will reach a national audience through ... more the Skin Health campaign and Colorescience, click ...
(Date:5/29/2015)... Dallas, TX (PRWEB) May 29, 2015 ... H1 2015” provides comprehensive information on the therapeutic ... different types of muscles in the body, leading ... strengthens R&D pipelines by identifying new targets and ... report on H1 2015 pipeline review of Axillary ...
(Date:5/29/2015)... Designed with the versatile athlete in mind, ... all new, exclusive line of supplementation called The 24/7 ... and greatest, high impact, result driven ingredients that have ... 24/7 Series can be used by anyone from bodybuilders ... fitness enthusiasts. There are no stimulant based ingredients that ...
(Date:5/29/2015)... 2015 The annual aesthetic meeting, put on ... held in Montreal from May 14-19th. This global event ... from around the world; dedicating itself exclusively to cosmetic medicine. ... renowned plastic surgeons to attend this year’s meeting. , ... Dr. Vitenas was given the honor of sitting at the ...
Breaking Medicine News(10 mins):Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3
... Corporation,(Nasdaq: DRRX ) announced today that James ... at the SIGnificant Investment Options,in Healthcare conference hosted ... at 2:45 p.m. EST. The conference is being ... York City., (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ), ...
... but significant association , , FRIDAY, Feb. 28 (HealthDay News) ... and taking vitamin E may even heighten the risk, ... supplement-taking habits and lung cancer incidence of almost 78,000 ... period. , "Our study of supplemental multivitamins, vitamin C, ...
... Pitching ... Legend Tommy John, SARASOTA, Fla. ... and retail company focused on providing,hearing aids with state-of-the-art fidelity, price ... Square Mall,(Sarasota) and Gulf View Mall (Port Richey)., Years ago, ...
... Feb. 29 Landauer, Inc. (NYSE:,LDR) announced today that ... of $0.50 per share for the second quarter of ... 2008, to shareholders of record,on March 14, 2008., ... analytical services to determine,occupational and environmental radiation exposure. For ...
... Calif., Feb. 29 Genoptix, Inc.,(Nasdaq: GXDX ), ... stock being offered by certain existing stockholders to,the public ... will not,receive any proceeds from the sale. The offer ... offering is being made through an underwriting syndicate led ...
... Feb. 29 /Xinhua-PRNewswire-FirstCall/ -- Qiao Xing,Mobile Communication Co., Ltd. ... one of China,s leading domestic manufacturers of mobile,handsets through ... launch of its new C7000A cardiograph mobile handset., ... Cardiograph function -- Users will be able to perform ...
Cached Medicine News:Health News:Vitamin E Supplements May Raise Lung Cancer Risk 2Health News:Vitamin E Supplements May Raise Lung Cancer Risk 3Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 3Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... Seven digital models cover the range from 2ul ... fluently. Volume lock design prevents inadvertent volume ... horizontal grip. Whole pipette is autoclavable at ... is all polypropylene. Suitable for one-handed operation. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: